Wednesday, January 30, 2019
The new treatment is being developed by pharmaceutical laboratory Accelerated Evolution Biotechnologies under the leadership of the CEO, Dr. Ilan Morad, according to the report.
"We believe we will offer a complete cure for cancer in a year," said Dan Aridor, chairman of the company's board. "Our cure for cancer will be effective from day one, will last a few weeks and will have minimal or no side effects at a much lower cost than most other treatments on the market."
The treatment, called "MuTaTo," will use a combination of anticancer peptides and a toxin that will specifically kill cancer cells.
The treatment will eventually be personalized and patients will receive a specific cocktail of drugs according to their type of cancer, Morad told the paper.
Despite the importance of the announcement, some voices question the functioning of the new treatment, considering, for example, that it has only been tested in mice.
In that regard, the deputy medical director of the National Office of the American Cancer Society, Len Lichtenfeld, said on the agency's blog that "it is clear that we all share the hope that they are correct."
"Unfortunately, we should be aware that this is far from an effective treatment for people with cancer, much less a cure," he said.
Finally, the expert noted that the Israeli researchers did not publicly show the data collected to support his ad, in addition to not divulging the evidence that shows that the treatment was successful in mice, specifying that so far all of them have done is an interview for a local media, published by the site publimetro.cl.
With information from the Chronicle.